2,184
Views
12
CrossRef citations to date
0
Altmetric
Oncology

Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia

, , , , , , , , & show all
Pages 289-299 | Accepted 10 Nov 2015, Published online: 30 Nov 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Jorge E. Cortes, Delphine Rea, Michael J. Mauro, Diana Tran, Pearl Wang, Kejal Jadhav, Aurore Yocolly & Koji Sasaki. (2023) Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib. Journal of Medical Economics 26:1, pages 915-923.
Read now
Ahmet Emre Eskazan. (2018) The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis. Journal of Medical Economics 21:7, pages 709-711.
Read now
Elias J. Jabbour, Jay Lin, Lisa R. Siegartel, Melissa Lingohr-Smith, Brandy Menges & Dinara Makenbaeva. (2017) Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase. Journal of Medical Economics 20:9, pages 1007-1012.
Read now

Articles from other publishers (9)

Franck-Emmanuel Nicolini, Françoise Huguet, Lynn Huynh, Churong Xu, Christophe Bouvier, Aurore Yocolly & Gabriel Etienne. (2023) A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation. Cancers 15:16, pages 4161.
Crossref
Massimo Breccia, Francesca Chiodi, Aurelio Pio Nardozza, Diletta Valsecchi, Valentina Perrone, Diego Sangiorgi, Elisa Giacomini, Maria Chiara Rendace, Paola Coco, Eleonora Premoli & Luca Degli Esposti. (2022) The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy. Advances in Therapy 40:3, pages 961-974.
Crossref
Melissa Beauchemin, Sheila Judge Santacroce, Kira Bona, Ha Dang, Sarah Alexander, Kamala Allen, Crystal De Los Santos, Beth Fisher, Yudy Muñeton-Castaño, Olivia Ponce, Sarah Vargas, Aaron Sugalski, Lillian Sung & Susan Parsons. (2022) Rationale and design of Children’s Oncology Group (COG) study ACCL20N1CD: financial distress during treatment of acute lymphoblastic leukemia in the United States. BMC Health Services Research 22:1.
Crossref
Rumjhum Agrawal, Joao Vieira, Jacqueline Ryan, Harish Negi, Tanvi Rajput, Regina Corbin & Ricardo Viana. (2022) A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia. PharmacoEconomics 40:12, pages 1159-1186.
Crossref
Ehab L. Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi & Annie Guérin. (2022) Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective. Journal of Health Economics and Outcomes Research 9:2.
Crossref
Ehab Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi & Annie Guérin. (2022) Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective. Journal of Health Economics and Outcomes Research 9:2, pages 30-36.
Crossref
Hsiao Ling Phuar, Charles E. Begley, Wenyaw Chan & Trudy Millard Krause. (2020) Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia. American Journal of Clinical Oncology 43:7, pages 517-525.
Crossref
Hsiao Ling PhuarCharles E. BegleyWenyaw ChanTrudy Millard Krause. (2019) Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study. Journal of Managed Care & Specialty Pharmacy 25:10, pages 1140-1150.
Crossref
Qian Jiang, Haibo Wang, Lu Yu & Robert Peter Gale. (2017) Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology 143:12, pages 2619-2630.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.